TRANSFORMING
RADIOISOTOPE
SUPPLY
By investing in R&D and expanding production capabilities, we can ensure a reliable supply of the medical isotopes that are critical to the success of theranostics.”
TRANSFORMING
RADIOISOTOPE
SUPPLY
Unique Technology for
Medical Isotope Production
Eden's Advantages
Eden’s efficiencies, capacities, costs, reliability, dual site redundancy and versatility will be superior to current reactors around the globe, which are few in number, were not designed for this purpose, and are plagued with age-related breakdowns and high operating costs, resulting in capacity limitations, supply chain disruptions and a progression of decommissioned sites.
Each of Eden’s LEU all-target reactor and production facilities in New Mexico and New Brunswick Canada will be capable of making more than 1.8 million patient doses annually of the critical new radiotherapy isotope Lutetium-177, as well as enough Molybdenum-99 capacity to service more than half of this global demand.
The Eden facility will be well positioned for a rapidly emerging new pipeline of radiotherapeutics that target and destroy specific cancer cells without the systemic side effects of chemo or immuno-therapies. Presently, there are >30 new radiotherapeutic drugs advancing through late stage FDA clinical trial process. The first FDA approved radioisotope therapy for prostate cancer, alone, has reached $2 billion in 2025 and is projected to be as high as $25 billion by 2032.